Vie. Nov 27th, 2020

Read full article here.

Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce it has initiated integration of CB2 Insights’ (CSE:CBII) medical cannabis Clinical Decision Support (CDS) tool.

The agreement will give the more than 4600 physicians and healthcare practitioners using Premier Health’s Juno EMR platform access to the industry’s only medical cannabis-specific CDS tool.  CB2 Insights’ CDS tool is designed to help incorporate medical cannabis into their patient’s treatment plans. This first-of-its-kind integration in the medical cannabis sector will allow physicians and healthcare practitioners to overcome many of the barriers they face from a lack of access to education, qualification factors, risks and benefits of cannabinoid therapy, all on a patient-specific basis using clinically-validated data.

“For the past 4 years, we have continued to work toward simplifying the process for a physician to gain required understanding amidst the disparate of clinically validate data sets available when considering cannabis as an option within a patient’s treatment plan,” said Prad Sekar, CEO of CB2 Insights. “We are now in a position to benefit from the aggregated and anonymized data gathered from over 300,000 patient visits in a clinical environment to power our CDS tool that will bring clinicians a point-of-care application to help them incorporate cannabis into their practice and create improved access for patients who can benefit from cannabinoid therapy.”

CB2 Insights, through its clinical arm in the US, operates 28 medical cannabis evaluation centers staffed with physicians and healthcare practitioners and creates both access for patients who qualify for medical cannabis as well as a center of excellence to study and understand the clinical outcomes of cannabinoid therapy. CB2 gathers data at the point-of-care in a HIPAA-compliant manner, both aggregated and anonymized, to study trends and outcomes that work to educate and support stakeholders including but not limited to physicians and other healthcare professionals.

Read full article here.

 

e-mail icon
Facebook icon
Twitter icon
LinkedIn icon
Reddit icon
Rate this article: 

Regional Marijuana News: 

Por admin